Pubertal induction in girls with Turner Syndrome.
Journal
Minerva endocrinology
ISSN: 2724-6116
Titre abrégé: Minerva Endocrinol (Torino)
Pays: Italy
ID NLM: 101777342
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
14
1
2021
medline:
28
1
2022
entrez:
13
1
2021
Statut:
ppublish
Résumé
Turner Syndrome (TS) is the most common female sex chromosome aneuploidy in females, and patients may present with hypergonadotropic hypogonadism due to gonadal dysgenesis. Timing and modalities of pubertal induction in these patients is still a matter of debate. Aim of this review was to focus on the latest update on pubertal induction in TS. Based on literature data, the following practical approach to this issue is recommended. Pubertal induction should begin between 11 and 12 years of age, starting with low doses of estradiol to preserve height potential. Transdermal 17β-Estradiol (17β-E2) could represent the first-choice induction regimen as it is more physiologic compared to an oral regimen and avoids the first-pass mechanism in the liver. In the case of poor compliance, administration of oral 17β-E2 or ethinyl estradiol could be offered. Incremental dose increases, approximately every 6 months, can contribute to mimic normal pubertal progression until adult dosing is reached over a 2- to 3-year period. Progestin should be added once breakthrough bleeding occurs or after 2 to 3 years of estrogen therapy or if ultrasound shows a mature uterus with thick endometrium. Treatment needs to be individualized and monitored by clinical assessment in relation to patient compliance and satisfaction. Well-designed prospective randomized clinical trials aimed to identify the best estrogen regimen for pubertal induction in TS girls are needed.
Identifiants
pubmed: 33435643
pii: S0391-1977.20.03285-X
doi: 10.23736/S2724-6507.20.03285-X
doi:
Substances chimiques
Estrogens
0
Estradiol
4TI98Z838E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM